ANA Therapeutics develops a novel vaccine to prevent coronavirus infection. Their vaccine aims to provide effective protection against current and future strains of the virus.

Anda is a mobility technology platform in Angola that provides motorcycle taxi services, asset financing, and delivery solutions, utilizing GPS tracking and a rigorous driver training program to ensure safety and reliability. The platform addresses the lack of accessible and safe transportation options for underserved communities by offering affordable rides and empowering local entrepreneurs with tailored financial products.

Artica Therapeutics uses covalent chemistry to develop orally bioavailable small‑molecule inhibitors that achieve antibody‑like potency and selectivity for autoimmune and inflammatory diseases. By forming irreversible bonds with disease‑relevant proteins, its “insurmountable” drugs maintain target engagement even under high stimulation, offering a convenient oral alternative to injectable biologics.

Avidicure develops Actibody, a proprietary triple‑agonistic antibody platform that simultaneously delivers primary activation, co‑stimulatory, and cytokine signals to immune cells, enabling sustained and localized immune activation. By genetically fusing engineered domains onto a human IgG scaffold and using AI‑driven in‑silico design, the molecules provide conditional activation at the target site, enhancing potency while reducing systemic toxicity for oncology and autoimmune applications.

This drug development company uses AI and machine learning to identify and develop clinical candidates for neurodegenerative diseases. Their focus is on translating aging science research into therapies that can combat conditions like Alzheimer's and Parkinson's.

CatalYm is developing a monoclonal antibody, visugromab, that neutralizes GDF-15 to reverse immune resistance mechanisms in solid tumors, thereby enhancing anti-tumor immune responses. This approach aims to improve treatment outcomes for cancer patients who are non-responsive to existing therapies, addressing a significant gap in current immunotherapy effectiveness.

Citryll is developing CIT-013, a first-in-class monoclonal antibody that inhibits the formation of Neutrophil Extracellular Traps (NETs) and enhances their clearance, targeting a key mechanism in immune-mediated inflammatory diseases. The company focuses on treating conditions such as Rheumatoid Arthritis and Hidradenitis Suppurativa, where NETs contribute significantly to inflammation.

Complement Therapeutics develops novel therapies that modulate the complement system to address unmet needs in complement‑mediated diseases, most notably geographic atrophy in age‑related macular degeneration. Its pipeline includes an AAV‑based gene therapy (CTx001) for retinal complement dysregulation and protein‑based candidates for systemic conditions, supported by a mass‑spectrometry platform that quantifies multiple complement proteins from a single blood sample for patient stratification and trial monitoring.

Confo Therapeutics utilizes a proprietary technology to stabilize functional conformations of G protein-coupled receptors (GPCRs), enabling the identification of previously inaccessible drug targets. The company focuses on developing novel GPCR modulators to provide disease-modifying treatments for patients with severe illnesses that currently lack effective therapies.

Dunad Therapeutics develops targeted protein degradation therapies using proprietary tunable covalent chemistry to selectively eliminate disease-causing proteins. This approach aims to provide durable treatment options for diseases driven by specific protein dysfunctions, enhancing therapeutic efficacy and patient outcomes.

ENSEM develops small molecule precision medicines for oncology using its Kinetic Ensemble® platform, which combines AI deep learning with experimental techniques to identify cryptic binding pockets in drug targets. This approach enables the discovery of therapeutic interventions for traditionally undruggable targets, addressing the challenge of drug resistance and enhancing treatment options for cancer patients.

Epsilogen develops immunoglobulin E (IgE) antibodies, specifically targeting solid tumors like ovarian cancer, to enhance treatment efficacy through improved tumor access and potency. Their lead candidate, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, demonstrating safety and early signs of clinical activity in patients with folate receptor alpha positive cancers.

FundaMental Pharma develops first-in-class NMDAR/TRPM4 interface inhibitors that selectively eliminate neurotoxic effects of extrasynaptic NMDA receptors while preserving synaptic receptor functions essential for neuronal survival and memory. This approach targets neurodegeneration, aiming to restore cognitive function and maintain overall brain health.

Kivu Bioscience develops next-generation antibody-drug conjugates (ADCs) utilizing site-specific conjugation technology, specifically targeting asparagine-297 to enhance homogeneity and stability while minimizing off-target toxicity. The company addresses the need for more effective cancer treatments by creating highly stable ADCs with optimized linker and payload combinations that improve therapeutic efficacy and patient tolerability.

Mironid is developing small-molecule therapeutics that target cAMP degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases. The company aims to address the significant unmet medical needs in the treatment landscape for these degenerative conditions.

Phloxe is a search engine that exclusively lists verified ethical companies, allowing consumers to find products aligned with their values. By utilizing AI-driven search capabilities, Phloxe addresses the challenge of identifying responsible brands, enabling guilt-free shopping experiences.

Phosphoenix develops a visual prosthesis that interfaces directly with the brain to restore functional vision for individuals lacking a functional retina or optic nerve. The technology utilizes high-density, ultra-flexible probes to stimulate the visual cortex, generating artificially perceived images. This implant aims to enable blind individuals to identify objects and navigate independently.

This company develops novel therapies for cardiovascular diseases by focusing on direct targeting of the heart muscle. They utilize expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to create advanced 3D cardiac in vitro models. These models support the discovery and development pipeline for new cardiac drugs.

Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.

Scenic Biotech develops genomics and immunotherapy technologies to identify and utilize genetic suppressors for therapeutic applications. Their platform targets disease pathways in neuro- and metabolic disorders, enabling the creation of disease-modifying therapies that offer new treatment options for patients.

This biotech company develops novel therapeutics that target the perpetual cycle of inflammation amplified by tissue and organ damage. Their technology aims to treat autoimmune, inflammatory, metabolic, and neurodegenerative diseases by blocking abnormal DNA release and subsequent inflammation.

TargED Biopharmaceuticals develops TGD001, a targeted thrombolytic therapy utilizing small antibodies for localized enzyme delivery to effectively treat various forms of thrombosis. This approach aims to enhance thrombolysis in patients suffering from conditions such as Immune Thrombotic Thrombocytopenic Purpura and Acute Ischemic Stroke, addressing a significant global health issue that contributes to over 16 million deaths annually.

Tesselate Bio is developing precision medicines that target synthetic lethality mechanisms to treat cancers with Homologous Recombination Deficiency (HRD) and other novel interactions. The company focuses on biomarker discovery and companion diagnostics to meet significant unmet needs in cancer therapy, aiming to improve patient outcomes and survival rates.

The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.